Atlas Trials

Recurrent Squamous Cell Lung Carcinoma

12 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Squamous Cell Lung Carcinoma

RecordFirmDate
Lung-MAP S1400K: c-MET Positive (NCT03574753)SWOG Cancer Research Network2018-03-16
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer (NCT03373760)SWOG Cancer Research Network2017-11-30
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer (NCT03377556)SWOG Cancer Research Network2017-03-03
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (NCT02785952)SWOG Cancer Research Network2015-12-29
Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer (NCT02536495)Erin Bertino2015-09-01
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches (NCT02785913)SWOG Cancer Research Network2014-11-01
Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer (NCT02965378)SWOG Cancer Research Network2014-10-01
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (NCT02766335)SWOG Cancer Research Network2014-07-31
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (NCT02154490)SWOG Cancer Research Network2014-07-08
Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches (NCT02926638)SWOG Cancer Research Network2014-06-16

Track Recurrent Squamous Cell Lung Carcinoma automatically

Every clearance here is in the API, with alerts when new ones post.